Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial - PubMed (original) (raw)

Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial

Sanjay Kalra. Diabetes Ther. 2016 Dec.

Abstract

This commentary analyzes the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which has reported the cardiovascular benefits of liraglutide. It places the results of this seminal trial in the context of the evolution of diabetes care, compares them with other recently published cardiovascular outcome trials, and suggests novel mechanisms to explain the benefits and properties of liraglutide. The editorial discusses the potential impact that LEADER will have on the prevention and management of diabetes and its vascular complications.

Keywords: Calorie restriction mimicry; Cardiovascular outcome trials; Cholelithiasis; ELIXA; EMPA-REG; Empagliflozin; Liraglutide; Lixisenatide.

PubMed Disclaimer

Similar articles

• Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.
  Suissa S. Suissa S. Diabetes Care. 2018 Feb;41(2):219-223. doi: 10.2337/dc17-1059. Diabetes Care. 2018. PMID: 29358464
• The kidney and cardiovascular outcome trials.
  Bloomgarden Z. Bloomgarden Z. J Diabetes. 2018 Feb;10(2):88-89. doi: 10.1111/1753-0407.12616. J Diabetes. 2018. PMID: 29031006
• Lessons From LEADER - All-round Leadership.
  Kalra S. Kalra S. Eur Endocrinol. 2016 Aug;12(2):76-78. doi: 10.17925/EE.2016.12.02.76. Epub 2016 Aug 28. Eur Endocrinol. 2016. PMID: 29632591 Free PMC article.
• [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
  Scheen AJ, Piérard L, Krzesinski JM, Paquot N. Scheen AJ, et al. Rev Med Liege. 2016 Sep;71(9):376-381. Rev Med Liege. 2016. PMID: 28383832 Review. French.
• Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
  Giugliano D, Meier JJ, Esposito K. Giugliano D, et al. Diabetes Obes Metab. 2019 May;21(5):1081-1087. doi: 10.1111/dom.13629. Epub 2019 Feb 14. Diabetes Obes Metab. 2019. PMID: 30609236 Review.

Cited by

• Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
  Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Nauck MA, et al. Diabetes Care. 2019 Oct;42(10):1912-1920. doi: 10.2337/dc19-0415. Epub 2019 Aug 9. Diabetes Care. 2019. PMID: 31399438 Free PMC article. Clinical Trial.
• Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus.
  Bretón-Romero R, Weisbrod RM, Feng B, Holbrook M, Ko D, Stathos MM, Zhang JY, Fetterman JL, Hamburg NM. Bretón-Romero R, et al. J Am Heart Assoc. 2018 Sep 18;7(18):e009379. doi: 10.1161/JAHA.118.009379. J Am Heart Assoc. 2018. PMID: 30371206 Free PMC article.
• Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.
  Boye KS, Botros FT, Haupt A, Woodward B, Lage MJ. Boye KS, et al. Diabetes Ther. 2018 Apr;9(2):637-650. doi: 10.1007/s13300-018-0377-5. Epub 2018 Feb 19. Diabetes Ther. 2018. PMID: 29460259 Free PMC article.
• Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
  Berkovic MC, Bilic-Curcic I, Herman Mahecic D, Gradiser M, Grgurevic M, Bozek T. Berkovic MC, et al. Diabetes Ther. 2017 Dec;8(6):1297-1308. doi: 10.1007/s13300-017-0324-x. Epub 2017 Oct 26. Diabetes Ther. 2017. PMID: 29076038 Free PMC article.
• Glycemic equipoise.
  Kalra S, John M, Unnikrishnan AG. Kalra S, et al. Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):18-20. doi: 10.4103/2230-8210.194361. Indian J Endocrinol Metab. 2017. PMID: 28217492 Free PMC article. No abstract available.

References

1. 1. Baruah MP, Kalra B, Kalra S. Patient centred approach in endocrinology: from introspection to action. Indian J Endocrinol Metab. 2012;16(5):679. doi: 10.4103/2230-8210.100629. - DOI - PMC - PubMed
2. 1. Chinenye S, Ogbera AO, Kalra S. Patient-centered care in diabetology: Sub-Saharan African perspectives. Afr J Diabetes Med. 2014;21(1):5–8.
3. 1. Kalra S, Megallaa MH, Jawad F. Patient-centered care in diabetology: from eminence-based, to evidence-based, to end user-based medicine. Indian J Endocrinol Metab. 2012;16(6):871. doi: 10.4103/2230-8210.102979. - DOI - PMC - PubMed
4. 1. John M, Unnikrishnan AG, Kalra S, Nair T. Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development? Indian Heart J. 2016;68(4):564–571. doi: 10.1016/j.ihj.2016.02.017. - DOI - PMC - PubMed
5. 1. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684. - DOI - PubMed

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations